Non-Hodgkin lymphoma (NHL) is a cancer of the lymphatic system, the network of vessels, nodes, and white blood cells that fights infection. It starts when lymphocytes, a type of white blood cell, grow out of control. There are more than 60 subtypes, ranging from slow-growing (indolent) to fast-growing (aggressive). The most common is diffuse large B-cell lymphoma (DLBCL), which accounts for roughly 1 in 3 cases in the United States and is aggressive but often curable when caught and treated well.
What non-Hodgkin lymphoma is, and how it differs from Hodgkin and leukemia
Lymphoma is cancer that starts in lymphocytes. Doctors split it into two broad families. Non-Hodgkin lymphoma is the larger, more varied family with dozens of subtypes. Hodgkin lymphoma is defined under the microscope by a specific abnormal cell, the Reed-Sternberg cell, tends to strike younger adults, and is one of the most curable cancers. The two are treated differently, so the biopsy diagnosis matters.
Lymphoma is not the same as leukemia, even though both are blood cancers that involve white blood cells. Lymphoma forms solid collections of cancer cells, usually in lymph nodes; leukemia generally circulates in the blood and bone marrow. They share some symptoms but follow different diagnostic and treatment paths.
The symptoms to watch for
The most common first sign is a swollen lymph node felt as a lump under the skin on the side of the neck, in the armpit, in the groin, or above the collarbone. These lumps are usually painless, which is part of why people ignore them. NHL can also cause a cluster of symptoms doctors call B symptoms: fever with no infection, drenching night sweats that soak the sheets, and unexplained weight loss. Other signs include persistent fatigue, itching, and a feeling of fullness or swelling in the abdomen.
Most swollen nodes are caused by ordinary infections, not cancer. The rule that matters: a node that keeps growing, or one that lasts more than two weeks without an obvious cause, should be checked.
The disparity: younger, later, and worse survival
Overall NHL incidence is higher in white Americans than in Black Americans. The disparity is not in who gets it. It is in how Black patients are diagnosed and how they fare. In a SEER analysis of 38,522 DLBCL cases, Black patients were diagnosed far younger and later: 65% of Black patients were 60 or younger at diagnosis versus 37% of white patients, and 52% of Black patients presented with advanced stage III/IV disease versus 44% of white patients (Shenoy et al., Cancer, 2011). More Black patients also arrived with B symptoms (31% versus 24%).
That survival gap is not explained by biology alone. When researchers studied real-world outcomes after CAR-T cell therapy for aggressive B-cell NHL, median progression-free survival was 11.5 months for white patients but only 3.5 months for Black patients, and insurance status tracked closely with survival (Karmali et al., Blood Advances, 2024). The pattern points at access, timing, and the financial and structural barriers to modern care rather than at the cancer itself.
Under-represented in the trials that define modern treatment
CAR-T cell therapy, which re-engineers a patient's own immune cells to attack lymphoma, has changed outcomes for relapsed aggressive NHL. But Black patients were nearly absent from the trials that won FDA approval for these therapies. Across the pivotal CAR-T trials for blood cancers, Black participants made up only about 2% to 5% of enrollees (Al Hadidi et al., JAMA Network Open, 2022). When a group is missing from the evidence, it is harder to know how a therapy performs for them, and harder to get referred to it.
The access gap continues after approval. CAR-T and stem-cell transplant are delivered at a limited number of specialized centers, often far from where patients live, and they require insurance coverage, caregiver support, and weeks of nearby housing. Each of those requirements falls harder on patients with fewer resources, which is why insurance type and geography keep showing up as predictors of who actually gets these treatments.
Risk factors
Most people with NHL have no clear cause, but several factors raise risk:
- A weakened immune system. HIV infection, organ transplant, and medicines that suppress immunity all increase NHL risk. Staying on top of HIV care matters here; see our guide to HIV prevention for Black Americans.
- Certain infections. Epstein-Barr virus, hepatitis C, Helicobacter pylori, and human T-cell leukemia/lymphoma virus are linked to specific subtypes.
- Autoimmune disease. Conditions such as rheumatoid arthritis, lupus, and Sjogren syndrome carry higher lymphoma risk.
- Age. Risk climbs after 60, and more than half of people diagnosed are 65 or older.
- Family history of lymphoma in a close relative.
How it is diagnosed
Diagnosis starts with a lymph node biopsy, the removal of all or part of an enlarged node so a pathologist can identify the exact subtype. That subtype drives every treatment decision. From there, doctors stage the disease with imaging, usually a PET-CT scan, and often a bone marrow biopsy to check whether the lymphoma has reached the marrow. Blood tests round out the picture. A needle aspirate alone is often not enough; getting a proper biopsy of the whole node is what gives an accurate diagnosis.
How it is treated
Treatment depends on the subtype and stage. Aggressive lymphomas like DLBCL are usually treated to cure with chemo-immunotherapy, most commonly the regimen known as R-CHOP, which pairs the antibody rituximab with chemotherapy. Radiation may be added for limited-stage disease. When the lymphoma comes back or does not respond, options include CAR-T cell therapy and high-dose chemotherapy with a stem-cell transplant. Slow-growing lymphomas may instead be watched closely before treatment starts. The takeaway: this is a treatable cancer, and for many people a curable one, when care is timely and complete.
How to get care
If you have a swollen node that is not resolving, start with a primary care visit and ask for a referral to a hematologist-oncologist. If you are diagnosed with an aggressive lymphoma, ask early whether you should be seen at a center that offers clinical trials, CAR-T cell therapy, and transplant, because access to those options shapes survival. You can find a Black or Black-serving clinician in our directory to start the conversation with a provider who takes your concerns seriously.
Frequently asked questions
Is non-Hodgkin lymphoma curable? ▼
Many cases are. Aggressive types such as DLBCL are often treated with the goal of cure, and most patients respond to first-line chemo-immunotherapy. Slow-growing types are usually not cured but can be controlled for years. The subtype and stage at diagnosis drive the outlook, which is why catching it earlier matters.
Why do Black patients have worse lymphoma survival if they get it less often? ▼
Incidence and survival are different problems. Black Americans are diagnosed with NHL less often overall, but studies show they present younger and at later stages and have worse DLBCL survival. Researchers tie much of the gap to access, timing of diagnosis, insurance, and under-representation in the trials behind modern therapies, not to the biology of the cancer alone.
What is the difference between non-Hodgkin lymphoma and Hodgkin lymphoma? ▼
Both are lymphomas, but Hodgkin lymphoma is defined by a specific cell (the Reed-Sternberg cell) seen on biopsy, tends to affect younger adults, and is among the most curable cancers. Non-Hodgkin lymphoma is a larger, more varied group with dozens of subtypes. They are staged similarly but treated differently, so the biopsy result decides the path.
How long can a swollen lymph node be normal before I worry? ▼
Most swollen nodes come from ordinary infections and shrink within a couple of weeks. A node that keeps growing, stays swollen beyond two to four weeks, is painless and firm, or comes with fevers, night sweats, or weight loss should be evaluated by a doctor and may need a biopsy.
What is CAR-T cell therapy and who can get it? ▼
CAR-T cell therapy re-engineers a patient's own immune cells to recognize and kill lymphoma, and it is used mainly for aggressive NHL that has relapsed or not responded to standard treatment. It is delivered at specialized centers and requires insurance coverage and caregiver support. Black patients have been underrepresented in CAR-T trials and have less access to it, so ask your oncologist early whether you are a candidate.
